Octagon Capital Advisors LP Taysha Gene Therapies, Inc. Transaction History
Octagon Capital Advisors LP
- $301 Million
- Q1 2025
A detailed history of Octagon Capital Advisors LP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 10,700,000 shares of TSHA stock, worth $29.1 Million. This represents 4.95% of its overall portfolio holdings.
Number of Shares
10,700,000
Previous 2,425,000
341.24%
Holding current value
$29.1 Million
Previous $3.37 Million
341.31%
% of portfolio
4.95%
Previous 0.35%
Shares
7 transactions
Others Institutions Holding TSHA
# of Institutions
133Shares Held
154MCall Options Held
70KPut Options Held
4.7K-
Avoro Capital Advisors LLC New York, NY20MShares$54.4 Million0.45% of portfolio
-
Rtw Investments, LP New York, NY18.8MShares$51.1 Million0.43% of portfolio
-
Morgan Stanley New York, NY16.8MShares$45.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$31.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$29.6 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $132M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...